Open this publication in new window or tab >>Show others...
2025 (English)In: NPJ Viruses, E-ISSN 2948-1767, Vol. 3, no 1, article id 62Article in journal (Refereed) Published
Abstract [en]
Although adenoviruses (AdVs) possess advantageous features as vectors, several challenges remain. These include a high prevalence of neutralizing antibodies against certain AdV types and the inability to efficiently transduce CAR-deficient cells and tissues. We showed previously that lactoferricin (Lfcin) enhances CAR-independent HAdV-C5 infection of epithelial and T-cells. Here, we assessed the ability of Lfcin to enable HAdV-C5 infection and transduction of human skeletal muscle cells. Lfcin increases HAdV-C5 infection and transduction of muscle myoblasts and myotubes by 10- to 30-fold. Enhanced infection correlates with increased cell binding, which differs mechanistically from that of coagulation factor X-mediated binding, as it remains unaffected by the removal of heparan sulfate. Additionally, Lfcin reduces the neutralizing effects of serum against HAdV-C5, suggesting it may shield key epitopes. By enabling viral binding to muscle cells and mitigating serum neutralization, Lfcin offers a novel strategy to improve the efficiency and durability of HAdV-C5-based gene delivery systems.
Place, publisher, year, edition, pages
Springer Nature, 2025
National Category
Medical Biotechnology (Focus on Cell Biology, (incl. Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) Microbiology in the Medical Area
Identifiers
urn:nbn:se:umu:diva-246913 (URN)10.1038/s44298-025-00144-7 (DOI)001578516300001 ()40826223 (PubMedID)2-s2.0-105022271801 (Scopus ID)
Funder
EU, Horizon Europe, 10109864Swedish Research Council, 2023-01831Swedish Research Council, 2019–0147Swedish Cancer Society, 22 2005 PjSwedish Cancer Society, CAN 2018/771
2025-11-282025-11-282025-11-28Bibliographically approved